X
TSHA icon

Xponance’s Taysha Gene Therapies TSHA Stock Holding History

Xponance’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156K Buy
22,881
+2,848
+14% +$16.9K ﹤0.01% 1656
2026
Q1 		$89.5K Buy
20,033
+2,815
+16% +$13.1K ﹤0.01% 1581
2025
Q4 		$94.7K Buy
17,218
+643
+4% +$3.12K ﹤0.01% 1473
2025
Q3 		$54.2K Buy
16,575
+3,738
+29% +$10.6K ﹤0.01% 1482
2025
Q2 		$29.7K Buy
12,837
+198
+2% +$430 ﹤0.01% 1482
2025
Q1 		$17.6K Buy
12,639
+714
+6% +$1.19K ﹤0.01% 1431
2024
Q4 		$20.6K Buy
11,925
+1,056
+10% +$2.19K ﹤0.01% 1434
2024
Q3 		$21.8K Buy
+10,869
New +$23.8K ﹤0.01% 1376

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Xponance's TSHA Position: Q2 2026 in Review

Xponance increased its Taysha Gene Therapies (TSHA) stake by 14% in Q2 2026, buying an estimated $16.9K and bringing the position to 22,881 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #1656.

Xponance first reported a position in TSHA in Q3 2024 and has held it in 8 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Xponance held 22,881 shares of Taysha Gene Therapies worth $156K as of Q2 2026.
  • Xponance bought 2,848 Taysha Gene Therapies shares in Q2 2026, an estimated $16.9K.
  • Taysha Gene Therapies made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1656 holding.
  • Xponance first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 8 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.